Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

: Gastric cancer (GC) is a highly heterogeneous disease and remains one of the major causes of cancer-related mortality worldwide. The vast majority of GC cases are adenocarcinomas including diffuse and intestinal GC that may differ in their incidence between Asian and non-Asian cohorts. The intestinal-subtype GC has declined over the past 50 years. In contrast to the intestinal-subtype adenocarcinoma, the incidence of diffuse-subtype GC, often associated with poor overall survival, has constantly increased in the USA and Europe. The aim of this study was to analyze the expression and clinical significance of steroid hormone receptors, two membrane-bound receptors ( and ), and several genes involved in epigenetic alterations. The findings may contribute to revealing events driving tumorigenesis and may aid prognosis. : Using mRNA from diffuse and intestinal GC tumor samples, the expression level of 11 genes, including those coding for sex hormone receptors (estrogen receptors and ), progesterone receptor () and androgen receptor (), and the putative relevant and receptor were determined by RT-qPCR. : In diffuse GC, the expression of , , and differed from their expression in the intestinal subtype. The expression of and was strongly increased in the diffuse subtype compared to the intestinal subtype (×1.90, = 0.001 and ×2.68, = 0.002, respectively). Overexpression of and was observed in diffuse GC (15 and 42%, respectively). The expression levels of and were strongly decreased in the intestinal subtype as compared to diffuse GC (×0.48, 0.005 and ×0.25, = 0.003, respectively; 37.5% and 56% underexpression). , , and showed notable differences for clinicopathological correlation in the diffuse and intestinal GC. A significant decrease of , , and in intestinal GC correlated with the absence of lymphatic invasion and lower TNM (I-II). In diffuse GC, among the hormone receptors, increases of and mainly correlated with expression of growth factors and receptors (, and ), and with genes involved in epithelial-mesenchymal transition ( and ) or cell migration (). Our results also report the strong decreased expression of and (two receptors that bind estrogen or xenoestrogens) in diffuse and intestinal subtypes. : Our study identified new target genes, namely hormone receptors and membrane receptors ( and ), whose expression is associated with an aggressive phenotype of diffuse GC, and revealed the importance of epigenetic factors (, , and ) in gastric cancers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12383840PMC
http://dx.doi.org/10.3390/biomedicines13081815DOI Listing

Publication Analysis

Top Keywords

hormone receptors
20
diffuse intestinal
16
intestinal subtype
12
receptors
11
diffuse
10
expression
9
receptors membrane
8
membrane receptors
8
gastric cancers
8
epigenetic alterations
8

Similar Publications

Hormonal receptor status and lymph nodes involvement in breast cancer: a retrospective study.

Cell Mol Biol (Noisy-le-grand)

September 2025

Assistant Professor of General Surgery, Department of Surgery, College of Medicine, University of Duhok, Kurdistan Region, Iraq.

Hormonal status and lymphatic invasion are two important prognostic factors among cases of breast cancer. This study aims to assess and evaluate the hormonal receptor status and lymph node involvement among female breast cancer patients in Duhok city, Kurdistan region, Iraq. A retrospective cross-sectional study was conducted, involving 156 diagnosed cases of breast cancer who had undergone surgical treatment and laboratory investigations at Azadi Teaching Hospital and Duhok Private Hospital for 30 months.

View Article and Find Full Text PDF

Recent research has shown that KATP channels in mouse taste bud cells enhance glucose taste signaling by depolarizing the cell when ATP is present. Relatedly, estradiol has been shown to enhance glucose sensing in human pancreatic β cells via closure of KATP channels. Since taste tissue has estradiol receptors, we linked these two observations and tested whether elevated estradiol may also enhance taste sensitivity and liking for glucose in humans.

View Article and Find Full Text PDF

Dysfunction of several WD40 family proteins causes diverse endocrine diseases. Until recently, MEP50, a WD40 protein, was considered a Gene of Unknown Significance (GUS) because no inherited diseases had been linked to its function. However, genetic inactivation of MEP50 in mouse models or somatic mutations in humans drive oncogenesis in several endocrine-related cancers, including those of the prostate, breast, and uterus.

View Article and Find Full Text PDF

Neurocognitive disorders represent a significant global health challenge and are characterized by progressive cognitive decline across conditions including Alzheimer's disease, mild cognitive impairment, and diabetes-related cognitive impairment. The hippocampus is essential for learning and memory and requires intact neuroplasticity to maintain cognitive function. Recent evidence has identified the brain insulin signaling pathway as a key regulator of hippocampal neuroplasticity through multiple cellular processes including synaptic plasticity, neurotransmitter regulation, and neuronal survival.

View Article and Find Full Text PDF

Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis.

Oncol Res

September 2025

The Breast Center, Cancer Hospital of Shantou University Medical College, Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Shantou, 515031, China.

Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant geographic disparities in its impact. While human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as trastuzumab, have improved outcomes for HER2-positive breast cancer, challenges like therapy resistance persist, highlighting the need for novel treatments. Recent developments in antibody-drug conjugates (ADCs), particularly disitamab vedotin (RC48), show promising efficacy in targeting both HER2-positive and HER2-low expression tumors, warranting further investigation through real-world studies to assess its broader clinical applicability.

View Article and Find Full Text PDF